JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Soumit Roy’s rating is based on Enliven Therapeutics’ strategic advancements and promising clinical trial progress. The company has successfully completed enrollment for its Phase 1b ENABLE trial for ELVN-001, targeting chronic myeloid leukemia (CML), and is on track to begin a pivotal Phase 3 trial in 2026. This progress indicates a strong potential for future growth and market positioning.
Furthermore, Enliven is expected to present significant data at the ASH 2025, showcasing the efficacy of ELVN-001 in patients with atypical fusion mutations. The company’s focus on determining optimal dosing for resistance mutations and the potential for a successful Phase 3 trial in the 2L+ setting further supports the Buy rating. These developments, along with anticipated updates on molecular response and survival endpoints, underscore the drug’s clinical benefits and potential market impact.
Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and Cullinan Management. According to TipRanks, Roy has an average return of -17.3% and a 26.41% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $48.00 price target.